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Identification of novel mutations in X-linked retinitis pigmentosa
families and implications for diagnostic testing
Abstract
PURPOSE: The goal of this study was to identify mutations in X-chromosomal genes associated with
retinitis pigmentosa (RP) in patients from Germany, The Netherlands, Denmark, and Switzerland.
METHODS: In addition to all coding exons of RP2, exons 1 through 15, 9a, ORF15, 15a and 15b of
RPGR were screened for mutations. PCR products were amplified from genomic DNA extracted from
blood samples and analyzed by direct sequencing. In one family with apparently dominant inheritance
of RP, linkage analysis identified an interval on the X chromosome containing RPGR, and mutation
screening revealed a pathogenic variant in this gene. Patients of this family were examined clinically
and by X-inactivation studies. RESULTS: This study included 141 RP families with possible
X-chromosomal inheritance. In total, we identified 46 families with pathogenic sequence alterations in
RPGR and RP2, of which 17 mutations have not been described previously. Two of the novel mutations
represent the most 3'-terminal pathogenic sequence variants in RPGR and RP2 reported to date. In exon
ORF15 of RPGR, we found eight novel and 14 known mutations. All lead to a disruption of open
reading frame. Of the families with suggested X-chromosomal inheritance, 35% showed mutations in
ORF15. In addition, we found five novel mutations in other exons of RPGR and four in RP2. Deletions
in ORF15 of RPGR were identified in three families in which female carriers showed variable
manifestation of the phenotype. Furthermore, an ORF15 mutation was found in an RP patient who
additionally carries a 6.4 kbp deletion downstream of the coding region of exon ORF15. We did not
identify mutations in 39 sporadic male cases from Switzerland. CONCLUSIONS: RPGR mutations
were confirmed to be the most frequent cause of RP in families with an X-chromosomal inheritance
pattern. We propose a screening strategy to provide molecular diagnostics in these families. 
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Purpose: The goal of this study was to identify mutations in X-chromosomal genes associated with retinitis pigmentosa
(RP) in patients from Germany, The Netherlands, Denmark, and Switzerland.
Methods: In addition to all coding exons of RP2, exons 1 through 15, 9a, ORF15, 15a and 15b of RPGR were screened
for mutations. PCR products were amplified from genomic DNA extracted from blood samples and analyzed by direct
sequencing. In one family with apparently dominant inheritance of RP, linkage analysis identified an interval on the X
chromosome containing RPGR, and mutation screening revealed a pathogenic variant in this gene. Patients of this family
were examined clinically and by X-inactivation studies.
Results: This study included 141 RP families with possible X-chromosomal inheritance. In total, we identified 46 families
with pathogenic sequence alterations in RPGR and RP2, of which 17 mutations have not been described previously. Two
of the novel mutations represent the most 3’-terminal pathogenic sequence variants in RPGR and RP2 reported to date.
In exon ORF15 of RPGR, we found eight novel and 14 known mutations. All lead to a disruption of open reading frame.
Of the families with suggested X-chromosomal inheritance, 35% showed mutations in ORF15. In addition, we found five
novel mutations in other exons of RPGR and four in RP2. Deletions in ORF15 of RPGR were identified in three families
in which female carriers showed variable manifestation of the phenotype. Furthermore, an ORF15 mutation was found in
an RP patient who additionally carries a 6.4 kbp deletion downstream of the coding region of exon ORF15. We did not
identify mutations in 39 sporadic male cases from Switzerland.
Conclusions: RPGR mutations were confirmed to be the most frequent cause of RP in families with an X-chromosomal
inheritance pattern. We propose a screening strategy to provide molecular diagnostics in these families.
Retinitis pigmentosa (RP) is clinically characterized by
night blindness, concentric constriction of visual fields,
pigment deposits predominantly in the midperiphery of the
retina, and attenuation of retinal vessels. It affects one in
3000–4000 individuals and can be caused by mutations in
more than 40 genes (Retnet; Retina International). The disease
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may be inherited as autosomal recessive, autosomal dominant,
or X-linked (XL) traits. Approximately 50% of the cases are
sporadic [1].
Most mutations lead to a similar phenotype, making
genotype-phenotype correlations difficult. Nevertheless,
mutations in XLRP genes are associated with a severe
phenotype in terms of onset and progression of the disease.
The two known RP-associated X-chromosomal genes are
designated RPGR (OMIM 312610) and RP2 (OMIM
312600) [2-4]. Additional loci on the X-chromosome have
been mapped, but the respective genes have not been
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identified [5-7]. Indeed, most XLRP cases can be explained
by mutations in RPGR and RP2 accounting for up to 80% and
20% of disease alleles, respectively. Moreover, RPGR
mutations underlie 10–20% of all familial RP cases, which is
higher than most other single RP loci [8,9].
The RPGR gene is composed of 23 exons, including the
alternatively spliced exons 9a, ORF15, 15a, and 15b [10-12].
Exon ORF15 is predominantly found in transcripts of the
retina and brain [13], whereas mRNAs including exons 1–19
are widely expressed [12]. The N-terminal part of RPGR
contains a domain homologous to the regulator of
chromosome condensation 1 (RCC1), the guanine-
nucleotide-exchange factor for the GTPase Ran that has been
shown to be important for the association with binding
partners. RPGR mutations are most frequently found in exon
ORF15, followed by exons 1–15 [9-12,14,15]. No mutations
have been identified in exons 16–19 so far. ORF15 contains
Figure 1. Location of novel RPGR and RP2 mutations identified in
this study. The schematic drawing shows novel mutations and their
approximate positions in RPGR (A) and RP2 (B). Alternatively
spliced exons are shown in light gray, whereas other exons are
depicted in black.
a purine-rich domain of approximately 1050 base pairs, which
is predicted to encode a repetitive glycine and glutamate
region at the C-terminus of the protein. In human, out of frame
deletions, duplications, or insertions are frequently found in
ORF15, whereas nonsense mutations are rare and disease-
relevant missense mutations have not been described. Two
canine animal models of ORF15 frame-shift mutations have
been published and closely resemble the human phenotype in
terms of disease onset and progression [16,17].
RT–PCR studies have suggested that splicing of both,
constitutive exons and the ORF15-internal repeat of RPGR,
generates numerous transcript variants [11,18]. This indicates
that splicing is an important regulator of RPGR function.
Recently, we have shown that a novel isoform of RPGR,
including exon 9a, is expressed predominantly in cones of the
human retina [10], which may explain why mutations in
RPGR can also lead to a predominant degeneration of cones
starting in the central part of the retina [19-22]. These findings
extend the phenotypic spectrum associated with RPGR
mutations and suggest a specific role of RPGR isoforms in the
survival of cones and rods of the human retina.
RP2 is composed of five coding exons, which are
translated to a widely expressed protein of 350 amino acids
[4]. The function of RP2 is not completely understood, but it
shows homology to cofactor C, a protein involved in the
ultimate step of gamma-tubulin folding, and interacts with
ADP ribosylation factor-like 3 [23]. Posttranslational acyl
modifications at the N-terminus of RP2 mediate its targeting
to the plasma membrane, and the disruption of the acylation
site leads to RP [24]. The majority of pathogenic sequence
alterations found in RP2 represent truncating mutations,
whereas missense mutations often locate to the cofactor C-like
domain of RP2.
The present study describes the results of mutational
screenings in RP families with possible XL inheritance
patterns. In addition to known sequence alterations, we found
several novel mutations in RPGR and RP2 and characterized
an XLRP family with variable disease expression in female
carriers. We identified a microdeletion breakpoint in addition
to an ORF15 frameshift mutation in a single RP patient. A
screening strategy for molecular diagnostic testing in patients
or families with presumed X-chromosomal inheritance is
discussed.
METHODS
Patients: Informed consent was obtained from each patient
and healthy control after explanation of the nature and
possible consequences of the study. Blood samples were
collected to perform routine molecular genetic testing for
genes associated with RP or related retinal diseases. We
collected a panel of 141 retinal degeneration patients with
possible XL inheritance patterns. Among those were 39
patients without history of additional affected family
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members, six cases with assumed dominant transmission and
males preferentially affected, and 90 cases with possible XL-
inheritance showing at least two affected male family member
and no male-to-male transmission. The latter group also
included male sibships. Six simplex cases were clinically
diagnosed with cone-rod dystrophy, whereas all others were
diagnosed with RP. Clinical evaluations of patients included
slit lamp examination, funduscopy, and Ganzfeld-
electroretinography (ERG). Ganzfeld-ERG was performed
according to standards of the International Society for Clinical
Electrophysiology of Vision using a LKC-UTAS 3000 ERG
device (LKC Technologies Inc., Gaithersburg, MD) or a
Nicolet Spirit examination unit (Nicolet, Madison, WI) [25,
26]. For scotopic ERG recordings, we employed a phase of
dark-adaptation preceded by single dim white and bright
white flashes for stimulation. Bright white flashes were used
for single responses and 30 Hz flicker responses in photopic
ERG measurements. Goldmann perimetry (Goldmann
perimetry module on the Octopus 101 visual field testing
device; Haag-Streit, Köniz, Switzerland), fundus
photography, and best corrected visual acuity testing were
often performed to complement the clinical characterization.
Furthermore, we collected blood samples from 15
individuals of an XLRP family, segregating the disease in
three generations (index 25085). In this family, ocular
examinations, as approved by the ethics committee of the
Institute of Human Genetics of the University Hospital of
Cologne, were done in II:3, III:7, and III:12 and included
refraction, best corrected visual acuity, intraocular pressure,
slit-lamp biomicroscopy, funduscopy, and color
discrimination test. ERG, dark adaptation and visual field
were also analyzed in these three patients.
Linkage analysis for an XLRP locus with variable
heterozygote manifestation: We analyzed DNA samples from
15 individuals of a family that segregates RP in three
generations (index patient 25085). PCR fragments of
polymorphic microsatellite markers were amplified using
fluorescent-labeled oligonucleotides and analyzed on an
ABI-377 DNA sequencer (Applied Biosystems, Darmstadt,
Germany). Genotypes were determined by GeneScan
software (Applied Biosystems). Data provided by the GDB
Human Genome Database were used as reference for allele
sizes. Segregation analysis was performed by genotyping
locus-specific microsatellite markers for the following AD RP
genes: NRL (RP27), CRX, RP1, PIM1K (RP9), IMPDH1
(RP10), CA4 (RP17), and FSCN2. Markers were not
informative for PRPF31, RDS, and RHO. Therefore, the entire
coding regions of the corresponding genes were sequenced in
the index patient (III:7). In PRPF3 and PRPF8, mutations
have only been described in exons 11 and 42, respectively.
These exons were directly sequenced. Primer sequences and
PCR conditions are available upon request. The RP31 locus
had not yet been described when this study was performed and
thus, was not analyzed [27].
To map the disease locus, we performed a genome-wide
linkage analysis using the Affymetrix GeneChip Human
Mapping 10K Array, version 2.0 (Affymetrix, Santa Clara,
CA). Genotypes were called by the GeneChip DNA Analysis
Software (GDAS v2.0; Affymetrix). Genders of samples were
verified by counting heterozygous single nucleotide
polymorphisms (SNPs) on the X chromosome. Relationship
errors were evaluated with the help of the program Graphical
Relationship Representation [28]. The program PedCheck
was applied to detect Mendelian errors [29], and data for SNPs
with such errors were removed from the data set. Non-
Mendelian errors were identified by using the program Merlin
[30] and unlikely genotypes for related samples were deleted.
Nonparametric linkage analysis using all genotypes of a
chromosome simultaneously was performed with Merlin.
Parametric linkage analysis was performed by a modified
version of the program Genehunter 2.1 [31,32] through
stepwise use of a sliding window with sets of 100 SNPs and
by the program Allegro [33] assuming autosomal dominant
inheritance with reduced penetrance and a disease allele
frequency of 0.0001. Haplotypes were reconstructed with
Allegro or Merlin and presented graphically with
HaploPainter [34]. All data handling was performed using the
graphical interface Alohomora [35].
Mutation screening: The genomic DNA of the index patient
panel was screened for disease-associated sequence
alterations in exon ORF15 of RPGR by direct sequencing of
PCR products. A single PCR fragment, spanning the entire
coding region of exon ORF15, was amplified from 100 ng
genomic DNA using primers ORF15-F3 and ORF15-R6
(Appendix 1). As described elsewhere, patients’ genomic
DNA was either extracted by a salting out method or by
affinity purification mediated by magnetic beads [36,37].
PCR was performed with either HotfireTaq (Solis Biodyne,
Tartu, Estonia) or HotstarTaq Polymerase (Qiagen AG,
Hombrechtikon, Switzerland) as recommended by the
manufacturers. Q-solution and 3µM MgCl2 were added to the
reaction mixture. Cycling conditions of the PCR were
conducted for 45 cycles as follows: initial denaturation 95 °C
for 15 min, denaturation 95 °C for 45 s, annealing 60 °C for
1 min, elongation 72 °C for 3.5 min. Subsequently, the PCR
fragments were sequenced (ABI 3100; Applied Biosystems,
Rotkreuz, Switzerland) with primers ORF15-R7b, -R8b, -R9,
-R5, -R4, and -F10 (Appendix 1). The sequenced PCR profiles
were compared to the RPGR reference database entry
NM_001034853 (NCBI database). If genomic DNA were
available only from female members of the family, sequence
analysis of ORF15 was occasionally not complete, since
polymorphic heterozygote deletions or duplications may
resulted in overlapping sequence spectrums. If no mutations in
RPGR exon ORF15 were detected, we subsequently analyzed
all coding exons of RP2 and the RPGR exons 1 through 15,
9a, 15a, and 15b, including flanking intronic sequences. RP2
mutational screening was performed using either single strand
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conformation polymorphism analysis or direct sequencing
[4] (Appendix 1). Long-range PCR was conducted as
recommended by the manufacturers (Expand long range PCR
system; Roche, Mannheim, Germany) using the primer
ORF15-F10 and ORF15–15a-R10 (annealing temperature of
60 °C; elongation time of 10 min). Potential mutations of RP2
or RPGR were verified by sequence analysis of the respective
position in either 100 or 300 control alleles. The database entry
BC043348 was used as reference sequence for RP2 mutation
analysis. The identified nucleotide substitutions and protein
consequences are described as recommended (for guidelines
see the Human Genome Variation Society) and, to be
comparable to previously published data, as suggested by
Sharon et al. [15] or Bader et al. [9].
X-chromosome inactivation studies: A nonrandom X-
inactivation may explain variable phenotypic expression in
females that carry a single RPGR mutation. To test this
possibility, we performed X-chromosome inactivation studies
and examined the methylation patterns at the androgen
receptor (AR) locus as described before [38]. Briefly, for each
proband, we prepared two reactions. In the first, 400 ng
genomic DNA were digested with HpaII (8 U) in a total
volume of 10 μl for 30 min at 37 °C. In the second reaction,
150 ng genomic DNA were incubated without enzyme.
Subsequent PCR amplification was done using
oligonucleotide primers AR-A (5′-CTT TCC AGA ATC TGT
TCC AG-3′) and AR-B (5′-AAG GTT GCC TGT TCC TCA
TC-3′) in a PTC-thermal cycler (MJ Research, BioRad,
München, Germany) at 95 °C for 1 min, 55 °C for 1 min, and
72 °C for 1 min for 35 cycles. About 2–10 μl of the product
was mixed with 2–6 μl loading buffer and run at 70 W for 3–
3.5 h on an 8% nondenaturing polyacrylamide gel. After
electrophoresis, the gel was silverstained for evaluation. DNA
samples of a male control as well as two female controls with
previously confirmed unilateral X-inactivation were included
into the analysis.
RESULTS
Identification of mutations: We analyzed DNAs from 141
patients with retinal degeneration for mutations in X-
chromosomal RP-associated genes. DNA was collected from
various geographical regions, including Germany,
Switzerland, Denmark, and The Netherlands and contained 90
samples from families indicative for an XL-inheritance
pattern. Within the subgroup of 90 index patients, we
identified 31 (35%) mutations in exon ORF15 of RPGR.
Among these ORF15 mutations, 14 sequence alterations had
been reported previously, whereas eight were novel mutations
(Figure 1A, Table 1). In addition to two nonsense mutations
leading to a premature stop codon, we identified three
different duplications, 16 distinct deletions, and one insertion.
All cause a frameshift and were predicted to result in altered
amino acids followed by a premature stop codon (Table 1).
We excluded that additional nucleotide variations in RP2 and
RPGR may explain the phenotype of RP in patients with
ORF15 mutations and performed mutation screenings in
exons 1 through 15, 9a, 15a, and 15b of RPGR and all coding
exons of RP2. In addition to pathogenic mutations, we
identified several polymorphic sequence alterations (Table 2
and Table 3).
The deletion c.2548delG in exon ORF15 of RPGR was
detected in two independent families. In one of them (index
patient 24731), the mother as well as three of her sons were
affected by RP, whereas one son and one daughter were
unaffected. Since the mother was affected, this suggests that
female carriers of this mutation can be affected by RP. The
second family, in which we found the mutation c.2548delG in
the index patient 10005, showed variable disease
manifestation in female carriers. The finding that two
apparently unrelated families with the same RPGR mutation
showed disease expression in female carriers, suggests a
genotype-phenotype correlation. Further families with this
mutation need to be analyzed to verify this observation.
In patient 2557, we identified the single bp deletion c.
3395delA at the 3’ end of exon ORF15 (Table 1). Remarkably,
the same patient had been shown to have an approximately
6.4 kb deletion in the RPGR gene [39]. We now have
determined the breakpoints in the genomic DNA to verify
whether the 6.4 kb deletion, in addition to c.3395delA, affects
the exon ORF15 coding region. We performed long-range
PCR and sequencing and found that the 6.4 kb deletion started
27 bp after the stop codon of exon ORF15 and ended 72 bp
downstream of exon 15a (Figure 2A,B,C). Thus, the larger
deletion of patient 2557 includes 6419 bp and removes exon
15a and 15b of RPGR, but does not affect the coding region
of exon ORF15. In contrast, the mutation c.3395delA removes
an adenine 62 bp upstream of the ORF15 stop codon.
Consequently, the mutation was predicted to result in a
frameshift at the 3’-terminal end of ORF15, which affects only
the last 21 amino acids and results in a premature stop codon
after inclusion of 19 RPGR-unrelated amino acids. The two
deletions found in the male index patient 2557 locate to one
allele at a distance of only 90 bp within RPGR.
In XLRP patients without an ORF15 mutation, we
screened the five exons of RP2 by direct sequencing and
identified five pathogenic sequence variations, which either
lead to a frameshift, an altered amino acid composition, or a
presumed splice defect of RP2 (Figure 1B, Table 1).
DNA from index patients who did not show mutations in
ORF15 and RP2 were analyzed for sequence variations in
exons 1 through 15, 9a, 15a, and 15b of RPGR. We were able
to identify pathogenic sequence alterations in six additional
XLRP cases. One mutation, found in exon 8, deletes two bp
of codon 271, introducing a frameshift to the transcript. Three
mutations affect intronic sequences close to RPGR exons and
presumably result in splice defects. Furthermore, two
mutations alter a glycine in either exon 6 or 7 of RPGR (Figure
Molecular Vision 2008; 14:1081-1093 <http://www.molvis.org/molvis/v14/a129> © 2008 Molecular Vision
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1A, Table 1). None of these sequence alterations were
identified in 100 to 300 control alleles. Sequence alterations
summarized in Table 3 likely represent polymorphisms.
RPGR ORF15 mutations were neither detected in 39
simplex male cases with RP, nor in six simplex male cases
affected by cone-rod dominated degenerations.
Analyses of a retinitis pigmentosa family with an assumed
dominant inheritance pattern: Among the six families with
dominant inheritance pattern, we found three deletions in exon
ORF15 of RPGR. In one of these six families (index patient
25085, Figure 3A) linkage analysis by microsatellite
genotyping was performed and excluded seven known ADRP
loci. Sequencing of PRPF31, RDS, RHO, HPRP3, and PRPF8
did not reveal causative mutations. Microarray-based linkage
analysis suggested an 11.5 Mb region on the X-chromosome
comprising the RPGR gene.
Subsequent analysis of RPGR identified a 2 bp deletion
within the alternatively spliced exon ORF15 (c.
2405_2406delAG, Table 1). This deletion was predicted to
result in a frameshift, an altered amino acid composition, and
a premature stop codon after 97 bp truncating the full length
protein by 320 amino acids. In addition, an in-frame 12 bp
TABLE 2. POLYMORPHIC SEQUENCE VARIATIONS IN EXON ORF15 OF RPGR FOUND IN X-LINKED RETINITIS PIGMENTOSA PATIENTS
Patient Deletions or duplications found in
exon ORF15 (1)
Deletions or
duplications found in
exon ORF15 (2)
Nucleotide
substitutions found in
exon ORF15 (1)
Nucleotide
substitutions
found in exon
ORF15 (2)
Protein change
resulting from
nucleotide
substitutions (1) (2)
24731 g.ORF15+1060_1080dup21 c.2813_2833dup21 g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
24731 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
24747 - - g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
24747 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
2678 - - g.ORF15+1813A>C c.3566A>C 3'UTR
2814 - - g.ORF15+1643C>T c.3396C>T p.N547N / p.N1132N
2814 - - g.ORF15+1677G>A c.3430G>A p.V559I / p.V1144I
2814 - - g.ORF15+1813A>C c.3566A>C 3'UTR
2865 g.ORF15+1307_1318delAGTGGAAGGGGA c.3060_3071del12 - - -
3044 g.ORF15+914_916delGGA c.2667_2669del3 g.ORF15+588G>A c.2341G>A p.A196T / p.A781T
25085 g.ORF15+1307_1318delAGTGGAAGGGGA c.3060_3071del12 - - -
The sequence alterations are either presented in approved nomenclature according to Human Genome Variation Society (2) or
as recommended by Bader et al., 2003 [9] and Sharon et al., 2003 [15] (1) (BC043348 and NM_001034853 were used as reference
sequence for, respectively, RP2 and RPGR mutation analysis).
TABLE 3. POLYMORPHIC SEQUENCE VARIATIONS IN EXONS 1 TO 15 OF RPGR FOUND IN X-LINKED RETINITIS PIGMENTOSA PATIENTS
Patient ID
Position in
RPGR
Nucleotide substitutions                                              Heterozygosity                   Protein
found in RPGR exons 1 to 15 SNP ID              frequency                    change
24731 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
24745 exon 10 c.1164G>A rs1801686 0.189 +/- 0.242 p.A388A
24747 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
24747 exon 9 c.1033A>G - 0.007** p.N345D
2249 exon 11 c.1367A>G - - p.Q456R
2604 exon 10 c.1164G>A rs1801686 0.189 +/- 0.242 p.A388A
2814 exon 9 c.1033A>G - 0.007** p.N345D
2814 intron 12 c.1507-101A>T rs5918520 - -
2557 intron 12 c.1507-101A>T rs5918520 - -
24520 intron 12 c.1507-101A>T rs5918520 - -
25428 intron 1 c.29-15G>A rs6651585 0.474 +/- 0.110 -
25428 exon 9 c.1033A>G - 0.007** p.N345D
25428 intron 12 c.1507-101A>T rs5918520 - -
24748* intron 4 c.310+10T>C - - -
The sequence alterations are presented in approved nomenclature according to Human Genome Variation Society
(NM_001034853 was used as reference sequence for mutation analysis). The asterisk (*) indicates that this sequence variant
was not detected in over 300 control alleles. The two asterisks (**) indicate that this value was published by Sharon et al., 2000
[15].
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ID
deletion, previously described as a polymorphism [9], was
found in each patient with the 2 bp deletion. This suggested
that both deletions were located on the same allele. The 12 bp
deletion was further downstream of the 2 bp deletion and
affected positions c.3060_3071del12. No additional sequence
alteration was identified in RP2 and RPGR. The segregation
of the deletions was in accordance with linkage data.
The mutation was identified in four males and four
females of the family, whereas six healthy female relatives did
not carry the mutation (Figure 3A). All male mutation carriers
showed the RP phenotype, whereas only two of the four
female carriers were affected (Figure 3A). In this family, the
ORF15 mutation caused a variable heterozygote
manifestation of the phenotype in females, although the
majority of previously reported RPGR mutations are
recessive.
Clinical evaluation and interviews with the patients
showed that the course of the disease, with respect to age-of-
onset and disease progression, varied both in affected males
and females. Males reported awareness of visual impairment
between seven and 24 years of age, and disease progression
varied from slow to rapid. Females first noticed visual
impairment at 24 years (II:2), 28 years (III:7), and 32 years
(II:3). Individual II:3 (mother of III:12; 61 years old) rapidly
Figure 2. Characterization of the
deletion breakpoint in patient 2557. A:
Schematic drawing of RPGR exons
ORF15, 15a, and 15b. Primers used for
long-range PCR are marked by arrows
and flank the 6419 bp deletion. B: Long-
range PCR for patient 2557 (male) and
a control sample (male). The difference
of the PCR products represents the 6.4
kb deletion in patient 2557. C: The
sequence profile shows the breakpoint
of the deletion in patient 2557. The open
reading frame of exon ORF15 was not
affected by the deletion. In total, 6419
bp were deleted, starting 27 bp after the
stop codon in ORF15 and ending 72 bp
after exon 15a. Note that exon 15a is
downstream of 15b. Thus, the deletion
affected both exons 15a and 15b of
RPGR.
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Figure 3. Characterization of a family with X-linked retinitis pigmentosa and variable expressivity in mutation carriers. A: Pedigree with three
generations. Circles represent females and squares represent males. Slashed symbols indicate deceased family members. Filled black symbols
denote family members with retinitis pigmentosa (RP), and circles with a dot indicate female mutation carriers who had no history of visual
complaints. Horizontal bars designate family members whose genotype was determined by molecular genetic testing. Arrow marks the index
patient 25085. The mutation c.2405_2406delAG in exon ORF15 of RPGR segregates with the disease in males, and shows variable
heterozygote manifestation in females. B: Fundus pictures of three affected family members show typical pigmentations found in the peripheral
retina of patients with RP. Patient age and gender are provided below each fundus photograph. C: Pattern of X-chromosome inactivation of
selected female family members. None showed a unilateral X-inactivation at the AR-locus. The following abbreviations and symbols are used:
control nonrandom X-inactivation (C-nr), control random X-inactivation (C-r), HpaII digestion (+), and no HpaII digestion (-).
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lost vision within a few years, a disease course similar to the
male family member III:4, who reported normal vision until
age 24, followed by rapid visual loss. In contrast to the severe
course of the disease in female II:3, kinetic perimetry, scotopic
and photopic ERG, and dark adaptation indicated mild
expression of RP in III:7 eight years after the diagnosis was
made. However, she had pigmentary deposits in the
midperiphery of her fundus (Figure 3B).
The phenotypic variability within female carriers of the
family might be caused by an altered X-chromosomal
inactivation. We analyzed the X-inactivation pattern in
different family members, but did not find skewed signal
intensities in any of the symptomatic female carriers (Figure
3C).
DISCUSSION
We identified 17 novel and 16 known mutations in RPGR and
RP2 by screening of 141 DNA samples from RP patients. In
the subgroup of 90 possible XLRP families, including also
male sibships, we identified five different RP2 mutations and
28 distinct pathogenic sequence alterations in RPGR.
Approximately 35% of the XLRP families described herein
showed mutations in exon ORF15 of RPGR. This detection
rate for ORF15 mutations was within the range found in other
studies [8,14]. RPGR exon ORF15 mutations have been
reported to occur either in 30% or 52% in North American
families with XLRP [15,40], whereas 43% were reported for
Spanish cohorts [41]. Furthermore, detection rates of 49%
have been described for families from France and 60% for
families from the UK/Ireland [11,14].
Of all published RPGR mutations, 55% have been
reported to reside in exon ORF15 [1]. We detected a total of 37
RPGR mutations, including 31 located to exon ORF15. Thus,
we identified over 80% of the RPGR mutations in ORF15, a
proportion higher than described recently [1]. These
variations in detection rates might be due to different ethnical
backgrounds of the patient cohorts.
Up to 28% of sporadic XLRP cases from France were
reported to carry mutations in exon ORF15 of RPGR [14]. In
contrast, we did not find ORF15 mutations in 39 sporadic
cases from Switzerland. This difference again indicates that
the ethnical background of the cohorts influences the
detection rate. Nevertheless, it might also be necessary to pre-
select sporadic cases for early-onset RP phenotypes, as done
by Pelletier et al. [14], to increase the chance to identify
ORF15 mutations in sporadic cases.
In one XLRP family, we found the mutation c.
968delAinsTCC in RP2. This pathogenic sequence alteration
deletes a single nucleotide and inserts three novel nucleotides
at the same position. It leads to a frameshift starting in exon
4 and was predicted to result in a premature stop in exon 5.
Moreover, the mutation inserts three nucleotides in the
penultimate position in exon 4 of RP2 and thus alters the
consensus sequence of the splice donor site. This might lead
to mis-splicing with increased exon 4 skipping from RP2
transcripts. The position of this mutation is, to the best of our
knowledge, the most 3’-terminal disease-associated variant in
RP2 identified so far. This also holds true for the mutation c.
3395delA (patient 2557) in exon ORF15 of RPGR. In the same
patient, an additional deletion of approximately 6.4 kb
removing RPGR exons 15a and 15b was identified, a
rearrangement that helped to identify the gene in 1996 [39].
In this study, we determined the breakpoint of this 6.4 kb
microdeletion and found that the coding region of ORF15 was
not affected. In contrast, the mutation c.3395delA
(p.Asn1132fs) of patient 2557 leads to a frameshift in the 3’-
terminal part of ORF15 and alters the composition of the last
21 amino acids of RPGR, which are not part of the repetitive
and highly charged region in ORF15. Interestingly, 3’-
terminal mutations in RPGR exon ORF15 are occasionally
associated with cone-rod degenerations rather than classic RP
[19-21,42]. However, in the case described herein, a typical
RP phenotype was observed. It is not clear whether or not the
microdeletion of over 6.4 kb influenced the phenotype in
patient 2557.
Disease expression in males with RPGR mutations is
severe. It has been shown previously that the phenotype of
female carriers of pathogenic RPGR mutations is highly
variable. Some exhibit severe symptoms, while others are
asymptomatic. We have identified three pathogenic sequence
alterations in the mutational hot spot exon ORF15 that lead to
disease expression also in female carriers. The mutation c.
2548delG was found in a family in which the mother, in
addition to three of her sons, was affected. The same mutation
occurred in a second family with reduced disease expression
in female carriers (family 10005). The finding that a mutation
leads to a phenotype only in a fraction of female carriers could
be due to genetic modifiers. We identified additional in-frame
variations in ORF15 that might influence the clinical picture
in female carriers. Nevertheless, in-frame deletions and
duplications were frequently described as polymorphisms of
exon ORF15, which makes it unlikely to be the only factor
causing the differences found in carriers. Other modifiers such
as age, environmental factors, additional changes in the
second allele of the carrier females, or genetic variability in
other genes may influence the disease expression. Further
investigations will identify and characterize the possible
modifiers that determine the clinical outcome of RPGR
mutations in female carriers. In contrast, no RP2 mutations
have been described that result into heterozygote carrier
manifestations.
The mutation c.2405_2406delAG, found in one of the
families with assumed dominant inheritance of this study, has
been described previously [43,44]. The family characterized
here showed severe retinal degeneration in males and mild
(III:7) to severe (II:3) ocular symptoms in two female carriers.
Moreover, we identified two female mutation carriers who
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had no history of visual complaints: II:7 (51 years old) and
III:11 (29 years old). In accordance with Rozet et al. [43], we
conclude that this mutation leads to variable heterozygote
manifestation of the phenotype. With the assumption that the
families are unrelated, this observation suggests a genotype-
phenotype correlation associated with the RPGR mutation c.
2405_2406delAG. We also identified an additional in-frame
(12 bp) deletion in all carriers of the pathogenic 2 bp deletion.
It is likely that the 12 bp deletion represents a polymorphism
as described by Bader et al. [9], although an additional effect
on the phenotype cannot be excluded. Skewed X chromosome
inactivation as an explanation of the largely variable disease
manifestations in females was not supported by our data. Full
expression of disease symptoms in females with an RPGR
mutation may be misleading in molecular analyses and
genetics counseling. Thus, ORF15 mutations in RPGR should
be excluded in families that seem to fit an AD pattern of RP,
but lack male-to-male transmission.
We propose a screening strategy for routine molecular
genetics testing of possible XLRP cases by direct sequencing.
Between 30% and 80% of mutations are found in exon ORF15
of RPGR [40,45], followed by mutation frequencies that are
similar for RP2 and RPGR exons 1 through 15. In total,
approximately 70%–80% of XLRP cases carry mutations in
RPGR and up to 20% in RP2. Based on these results and to
keep costs low, we recommend beginning with the screening
of an XLRP male patient by ORF15 mutation analysis. Our
approach to amplify the complete exon ORF15 in a single
PCR reaction reduces costs and effort. After identification of
an ORF15 mutation, the molecular diagnosis might be
considered as confirmed, since patients with an additional
mutation in exons 1 through 15 of RPGR and RP2 have not
been reported. Nevertheless, this cannot be excluded, and a
complete screening of known XLRP genes should be offered.
In addition, the segregation of the ORF15 mutation within the
family might be verified. If no ORF15 mutation is identified,
we recommend to continue the screen for mutations with RP2
rather than RPGR. This recommendation is based on the fact
that RP2 is composed of five exons only, whereas 15 exons
need to be screened to complete the sequence analysis of
RPGR without any clear benefit in terms of likelihood to
detect the causative mutation.
So far, no RP2 mutation has been identified in families
with likely dominant inheritance pattern, except for a single
case, where the only affected female showed a structural
chromosome aberration and a unilateral X-inactivation due to
a balanced X-autosome translocation [14]. In contrast,
dominant inheritance was reported for a couple of RPGR
mutations [43,46]. Furthermore, ORF15 mutations have also
been associated with phenotypes of the central part of the
retina, including cone-rod or cone dystrophies and atrophic
macular degeneration [19-21,42]. Consequently, in XLRP
cases with manifestations of the phenotype in females or in
patients with X-linked cone-dominated retinopathies, we
recommend screening exon ORF15 first, followed by the
other exons of RPGR.
In addition to the phenotype of RP, mutations in exons 6,
8, and 10 of RPGR have been associated with features of
primary ciliary dyskinesia, hearing dysfunction, sinusitis, and
recurrent infections [47-50]. Thus, in XLRP cases with
additional phenotypes, the best candidate region of RPGR
seems to be exons 1 through 15.
ACKNOWLEDGMENTS
We thank the following for financial support: Velux
Foundation (Switzerland), Olga Mayenfish Foundation
(Switzerland), Novartis Foundation (Switzerland),
‘Schweizerischer Fonds zur Verhütung und Bekämpfung der
Blindheit’ (Switzerland), Foundation Fighting Blindness,
British Retinitis Pigmentosa Society, Deutsche
Forschungsgemeinschaft (DFG LO 457/3 and LO 457/5),
Maria-Pesch-Stiftung, the CEC (EVI-GENORET LSHG-
CT-2005–512036), and De Nederlandse Vereniging ter
Voorkoming van Blindheid (ANVVB). We also thank E.M.
Sankila, E. van Nouhuys, M.J. van Shooneveld, C.W.R.J.
Cremers, C.B. Hoyng, and L.I. van den Born for help in
counseling patients. We are grateful to Birgit Langer and
Ursula Biendl (ERG), Jaya Balakrishnan for technical
assistance, and we thank Gabor Matyas for sequencing
support. We are indebted to the families who participated in
this study.
REFERENCES
1. Shu X, Black GC, Rice JM, Hart-Holden N, Jones A, O'Grady
A, Ramsden S, Wright AF. RPGR mutation analysis and
disease: an update. Hum Mutat 2007; 28:322-8. [PMID:
17195164]
2. Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A,
Edgar A, Carvalho MR, Achatz H, Hellebrand H, Lennon A,
Migliaccio C, Porter K, Zrenner E, Bird A, Jay M, Lorenz B,
Wittwer B, D'Urso M, Meitinger T, Wright A. A gene (RPGR)
with homology to the RCC1 guanine nucleotide exchange
factor is mutated in X-linked retinitis pigmentosa (RP3). Nat
Genet 1996; 13:35-42. [PMID: 8673101]
3. Roepman R, van Duijnhoven G, Rosenberg T, Pinckers AJ,
Bleeker-Wagemakers LM, Bergen AAB, Post J, Beck A,
Reinhardt R, Ropers HH, Cremers FPM, Berger W. Positional
cloning of the gene for X-linked retinitis pigmentosa 3:
homology with the guanine-nucleotide-exchange factor
RCC1. Hum Mol Genet 1996; 5:1035-41. [PMID: 8817343]
4. Schwahn U, Lenzner S, Dong J, Feil S, Hinzmann B, van
Duijnhoven G, Kirschner R, Hemberger M, Bergen AAB,
Rosenberg T, Pinckers AJ, Fundele R, Rosenthal A, Cremers
FPM, Ropers HH, Berger W. Positional cloning of the gene
for X-linked retinitis pigmentosa 2. Nat Genet 1998;
19:327-32. [PMID: 9697692]
5. Melamud A, Shen GQ, Chung D, Xi Q, Simpson E, Li L,
Peachey NS, Zegarra H, Hagstrom SA, Wang QK, Traboulsi
EI. Mapping a new genetic locus for X linked retinitis
pigmentosa to Xq28. J Med Genet 2006; 43:e27. [PMID:
16740911]
Molecular Vision 2008; 14:1081-1093 <http://www.molvis.org/molvis/v14/a129> © 2008 Molecular Vision
1090
6. Hardcastle AJ, Thiselton DL, Zito I, Ebenezer N, Mah TS,
Gorin MB, Bhattacharya SS. Evidence for a new locus for X-
linked retinitis pigmentosa (RP23). Invest Ophthalmol Vis
Sci 2000; 41:2080-6. [PMID: 10892847]
7. Gieser L, Fujita R, Goring HH, Ott J, Hoffman DR, Cideciyan
AV, Birch DG, Jacobson SG, Swaroop A. A novel locus
(RP24) for X-linked retinitis pigmentosa maps to Xq26–27.
Am J Hum Genet 1998; 63:1439-47. [PMID: 9792872]
8. Ferreira PA. Insights into X-linked retinitis pigmentosa type
3,  allied  diseases  and  underlying  pathomechanisms.
Hum Mol Genet 2005; 14:R259-67. [PMID: 16244324]
9. Bader I, Brandau O, Achatz H, Apfelstedt-Sylla E, Hergersberg
M, Lorenz B, Wissinger B, Wittwer B, Rudolph G, Meindl
A, Meitinger T. X-linked retinitis pigmentosa: RPGR
mutations in most families with definite X linkage and
clustering of mutations in a short sequence stretch of exon
ORF15. Invest Ophthalmol Vis Sci 2003; 44:1458-63.
[PMID: 12657579]
10. Neidhardt J, Glaus E, Barthelmes D, Zeitz C, Fleischhauer J,
Berger W. Identification and characterization of a novel
RPGR isoform in human retina. Hum Mutat 2007;
28:797-807. [PMID: 17405150]
11. Vervoort R, Lennon A, Bird AC, Tulloch B, Axton R, Miano
MG, Meindl A, Meitinger T, Ciccodicola A, Wright AF.
Mutational hot spot within a new RPGR exon in X-linked
retinitis pigmentosa. Nat Genet 2000; 25:462-6. [PMID:
10932196]
12. Kirschner R, Rosenberg T, Schultz-Heienbrok R, Lenzner S,
Feil S, Roepman R, Cremers FPM, Ropers HH, Berger W.
RPGR transcription studies in mouse and human tissues
reveal a retina-specific isoform that is disrupted in a patient
with X-linked retinitis pigmentosa. Hum Mol Genet 1999;
8:1571-8. [PMID: 10401007]
13. Kirschner R, Erturk D, Zeitz C, Sahin S, Ramser J, Cremers
FPM, Ropers HH, Berger W. DNA sequence comparison of
human and mouse retinitis pigmentosa GTPase regulator
(RPGR) identifies tissue-specific exons and putative
regulatory elements. Hum Genet 2001; 109:271-8. [PMID:
11702207]
14. Pelletier V, Jambou M, Delphin N, Zinovieva E, Stum M,
Gigarel N, Dollfus H, Hamel C, Toutain A, Dufier JL, Roche
O, Munnich A, Bonnefont JP, Kaplan J, Rozet JM.
Comprehensive survey of mutations in RP2 and RPGR in
patients affected with distinct retinal dystrophies: genotype-
phenotype correlations and impact on genetic counseling.
Hum Mutat 2007; 28:81-91. [PMID: 16969763]
15. Sharon D, Sandberg MA, Rabe VW, Stillberger M, Dryja TP,
Berson EL. RP2 and RPGR Mutations and Clinical
Correlations in Patients with X–Linked Retinitis Pigmentosa.
Am J Hum Genet 2003; 73:1131-46. [PMID: 14564670]
16. Beltran WA, Hammond P, Acland GM, Aguirre GD. A
frameshift mutation in RPGR exon ORF15 causes
photoreceptor degeneration and inner retina remodeling in a
model of X-linked retinitis pigmentosa. Invest Ophthalmol
Vis Sci 2006; 47:1669-81. [PMID: 16565408]
17. Zhang Q, Acland GM, Wu WX, Johnson JL, Pearce-Kelling S,
Tulloch B, Vervoort R, Wright AF, Aguirre GD. Different
RPGR exon ORF15 mutations in Canids provide insights into
photoreceptor cell degeneration. Hum Mol Genet 2002;
11:993-1003. [PMID: 11978759]
18. Hong DH, Li T. Complex expression pattern of RPGR reveals
a role for purine-rich exonic splicing enhancers. Invest
Ophthalmol Vis Sci 2002; 43:3373-82. [PMID: 12407146]
19. Ayyagari R, Demirci FY, Liu J, Bingham EL, Stringham H,
Kakuk LE, Boehnke M, Gorin MB, Richards JE, Sieving PA.
X-linked recessive atrophic macular degeneration from
RPGR mutation. Genomics 2002; 80:166-71. [PMID:
12160730]
20. Demirci FY, Rigatti BW, Wen G, Radak AL, Mah TS, Baic CL,
Traboulsi EI, Alitalo T, Ramser J, Gorin MB. X-linked cone-
rod dystrophy (locus COD1): identification of mutations in
RPGR exon ORF15. Am J Hum Genet 2002; 70:1049-53.
[PMID: 11857109]
21. Yang Z, Peachey NS, Moshfeghi DM, Thirumalaichary S,
Chorich L, Shugart YY, Fan K, Zhang K. Mutations in the
RPGR gene cause X-linked cone dystrophy. Hum Mol Genet
2002; 11:605-11. [PMID: 11875055]
22. Ebenezer ND, Michaelides M, Jenkins SA, Audo I, Webster
AR, Cheetham ME, Stockman A, Maher ER, Ainsworth JR,
Yates JR, Bradshaw K, Holder GE, Moore AT, Hardcastle
AJ. Identification of novel RPGR ORF15 mutations in X-
linked progressive cone-rod dystrophy (XLCORD) families.
Invest Ophthalmol Vis Sci 2005; 46:1891-8. [PMID:
15914600]
23. Evans RJ, Hardcastle AJ, Cheetham ME. Focus on molecules:
X-linked Retinitis Pigmentosa 2 protein, RP2. Exp Eye Res
2006; 82:543-4. [PMID: 16310188]
24. Schwahn U, Paland N, Techritz S, Lenzner S, Berger W.
Mutations in the X-linked RP2 gene cause intracellular
misrouting and loss of the protein. Hum Mol Genet 2001;
10:1177-83. [PMID: 11371510]
25. Gerber DM, Munier FL, Niemeyer G. Cross-sectional study of
visual acuity and electroretinogram in two types of dominant
drusen. Invest Ophthalmol Vis Sci 2003; 44:493-6. [PMID:
12556373]
26. Marmor MF, Zrenner E. Standard for clinical
electroretinography (1994 update). Doc Ophthalmol 1995;
89:199-210. [PMID: 7555587]
27. Papaioannou M, Chakarova CF, Prescott DC, Waseem N, Theis
T, Lopez I, Gill B, Koenekoop RK, Bhattacharya SS. A new
locus (RP31) for autosomal dominant retinitis pigmentosa
maps to chromosome 9p. Hum Genet 2005; 118:501-3.
[PMID: 16189705]
28. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. GRR:
graphical representation of relationship errors.
Bioinformatics 2001; 17:742-3. [PMID: 11524377]
29. O'Connell JR, Weeks DE. PedCheck: a program for
identification of genotype incompatibilities in linkage
analysis. Am J Hum Genet 1998; 63:259-66. [PMID:
9634505]
30. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin–
rapid analysis of dense genetic maps using sparse gene flow
trees. Nat Genet 2002; 30:97-101. [PMID: 11731797]
31. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric
and nonparametric linkage analysis: a unified multipoint
approach. Am J Hum Genet 1996; 58:1347-63. [PMID:
8651312]
32. Strauch K, Fimmers R, Kurz T, Deichmann KA, Wienker TF,
Baur MP. Parametric and nonparametric multipoint linkage
analysis with imprinting and two-locus-trait models:
Molecular Vision 2008; 14:1081-1093 <http://www.molvis.org/molvis/v14/a129> © 2008 Molecular Vision
1091
application to mite sensitization. Am J Hum Genet 2000;
66:1945-57. [PMID: 10796874]
33. Gudbjartsson DF, Jonasson K, Frigge ML, Kong A. Allegro, a
new computer program for multipoint linkage analysis. Nat
Genet 2000; 25:12-3. [PMID: 10802644]
34. Thiele H, Nurnberg P. HaploPainter: a tool for drawing
pedigrees with complex haplotypes. Bioinformatics 2005;
21:1730-2. [PMID: 15377505]
35. Ruschendorf F, Nurnberg P. ALOHOMORA: a tool for linkage
analysis using 10K SNP array data. Bioinformatics 2005;
21:2123-5. [PMID: 15647291]
36. Neidhardt J, Barthelmes D, Farahmand F, Fleischhauer JC,
Berger W. Different amino acid substitutions at the same
position in rhodopsin lead to distinct phenotypes. Invest
Ophthalmol Vis Sci 2006; 47:1630-5. [PMID: 16565402]
37. Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 1988; 16:1215. [PMID: 3344216]
38. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont
JW. Methylation of HpaII and HhaI sites near the
polymorphic CAG repeat in the human androgen-receptor
gene correlates with X chromosome inactivation. Am J Hum
Genet 1992; 51:1229-39. [PMID: 1281384]
39. Roepman R, Bauer D, Rosenberg T, van Duijnhoven G, van de
Vosse E, Platzer M, Rosenthal A, Ropers HH, Cremers FPM,
Berger W. Identification of a gene disrupted by a
microdeletion in a patient with X-linked retinitis pigmentosa
(XLRP). Hum Mol Genet 1996; 5:827-33. [PMID: 8776599]
40. Breuer DK, Yashar BM, Filippova E, Hiriyanna S, Lyons RH,
Mears AJ, Asaye B, Acar C, Vervoort R, Wright AF,
Musarella MA, Wheeler P, MacDonald I, Iannaccone A,
Birch D, Hoffman DR, Fishman GA, Heckenlively JR,
Jacobson SG, Sieving PA, Swaroop A. A comprehensive
mutation analysis of RP2 and RPGR in a North American
cohort of families with X-linked retinitis pigmentosa. Am J
Hum Genet 2002; 70:1545-54. [PMID: 11992260]
41. Garcia-Hoyos M, Garcia-Sandoval B, Cantalapiedra D, Riveiro
R, Lorda-Sánchez I, Trujillo-Tiebas MJ, Rodriguez de Alba
M, Millan JM, Baiget M, Ramos C, Ayuso C. Mutational
screening of the RP2 and RPGR genes in Spanish families
with X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci
2006; 47:3777-82. [PMID: 16936086]
42. Mears AJ, Hiriyanna S, Vervoort R, Yashar B, Gieser L,
Fahrner S, Daiger SP, Heckenlively JR, Sieving PA, Wright
AF, Swaroop A. Remapping of the RP15 locus for X-linked
cone-rod degeneration to Xp11.4-p21.1, and identification of
a de novo insertion in the RPGR exon ORF15. Am J Hum
Genet 2000; 67:1000-3. [PMID: 10970770]
43. Rozet JM, Perrault I, Gigarel N, Souied E, Ghazi I, Gerber S,
Dufier JL, Munnich A, Kaplan J. Dominant X linked retinitis
pigmentosa is frequently accounted for by truncating
mutations in exon ORF15 of the RPGR gene. J Med Genet
2002; 39:284-5. [PMID: 11950860]
44. Jin ZB, Liu XQ, Hayakawa M, Murakami A, Nao-i N.
Mutational analysis of RPGR and RP2 genes in Japanese
patients with retinitis pigmentosa: identification of four
mutations. Mol Vis 2006; 12:1167-74. [PMID: 17093403]
45. Vervoort R, Wright AF. Mutations of RPGR in X-linked
retinitis pigmentosa (RP3). Hum Mutat 2002; 19:486-500.
[PMID: 11968081]
46. Banin E, Mizrahi-Meissonnier L, Neis R, Silverstein S, Magyar
I, Abeliovich D, Roepman R, Berger W, Rosenberg T, Sharon
D. A non-ancestral RPGR missense mutation in families with
either recessive or semi-dominant X-linked retinitis
pigmentosa. Am J Med Genet A 2007; 143:1150-8. [PMID:
17480003]
47. Moore A, Escudier E, Roger G, Tamalet A, Pelosse B, Marlin
S, Clément A, Geremek M, Delaisi B, Bridoux AM, Coste A,
Witt M, Duriez B, Amselem S. RPGR is mutated in patients
with a complex X linked phenotype combining primary
ciliary dyskinesia and retinitis pigmentosa. J Med Genet
2006; 43:326-33. [PMID: 16055928]
48. Iannaccone A, Breuer DK, Wang XF, Kuo SF, Normando EM,
Filippova E, Baldi A, Hiriyanna S, MacDonald CB, Baldi F,
Cosgrove D, Morton CC, Swaroop A, Jablonski MM. Clinical
and immunohistochemical evidence for an X linked retinitis
pigmentosa syndrome with recurrent infections and hearing
loss in association with an RPGR mutation. J Med Genet
2003; 40:e118. [PMID: 14627685]
49. Koenekoop RK, Loyer M, Hand CK, Al Mahdi H, Dembinska
O, Beneish R, Racine J, Rouleau GA. Novel RPGR mutations
with distinct retinitis pigmentosa phenotypes in French-
Canadian families. Am J Ophthalmol 2003; 136:678-87.
[PMID: 14516808]
50. Zito I, Downes SM, Patel RJ, Cheetham ME, Ebenezer ND,
Jenkins SA, Bhattacharya SS, Webster AR, Holder GE, Bird
AC, Bamiou DE, Hardcastle AJ. RPGR mutation associated
with retinitis pigmentosa, impaired hearing, and
sinorespiratory infections. J Med Genet 2003; 40:609-15.
[PMID: 12920075]
51. Hardcastle AJ, Thiselton DL, Van Maldergem L, Saha BK, Jay
M, Plant C, Taylor R, Bird AC, Bhattacharya S. Mutations in
the RP2 gene cause disease in 10% of families with familial
X-linked retinitis pigmentosa assessed in this study. Am J
Hum Genet 1999; 64:1210-5. [PMID: 10090907]
52. Prokisch H, Hartig M, Hellinger R, Meitinger T, Rosenberg T.
A population-based epidemiological and genetic study of X-
linked retinitis pigmentosa. Invest Ophthalmol Vis Sci 2007;
48:4012-8. [PMID: 17724181]
53. Yokoyama A, Maruiwa F, Hayakawa M, Kanai A, Vervoort R,
Wright AF, Yamada K, Niikawa N, Naōi N. Three novel
mutations of the RPGR gene exon ORF15 in three Japanese
families with X-linked retinitis pigmentosa. Am J Med Genet
2001; 104:232-8. [PMID: 11754050]
54. Pusch CM, Broghammer M, Jurklies B, Besch D, Jacobi FK.
Ten novel ORF15 mutations confirm mutational hot spot in
the RPGR gene in European patients with X-linked retinitis
pigmentosa. Hum Mutat 2002; 20:405. [PMID: 12402343]
Molecular Vision 2008; 14:1081-1093 <http://www.molvis.org/molvis/v14/a129> © 2008 Molecular Vision
1092
Appendix 1: Primer combinations used to amplify and sequence RPGR or
RP2 exons including flanking intronic regions.
To access the data, click or select the words “Appendix 1”. This will initiate the download of a PDF file.
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